Publications by authors named "Christopher Zimmer"

Claim this Profile
V
Venous Thromboembolism in Foot and Ankle Trauma.
Naohiro Shibuya, Christopher Zimmer, Danial C Jupiter

Clin Podiatr Med Surg· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Paul B Watkins, James H Lewis, Neil Kaplowitz, David H Alpers, Jaime D Blais, Christopher A Zimmer

Drug Saf· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approach to investigate the cytotoxicity of nanomaterials using single cell mechanics.
Christopher C Zimmer, Ying X Liu, Joshua T Morgan, Guohua Yang, Kang-Hsin Wang

J Phys Chem B· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Muthiah Vaduganathan, Mihai Gheorghiade, Peter S Pang, Marvin A Konstam, Faiez Zannad, Christopher Zimmer

J Cardiovasc Med (Hagerstown)· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
James E Udelson, Martin Bilsker, Paul J Hauptman, Rafael Sequeira, Ignatius Thomas, Christopher Zimmer

J Card Fail· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
Philip L Cyr, Katherine A Slawsky, Natalia Olchanski, Holly B Krasa, Thomas F Goss, Christopher Zimmer

Am J Health Syst Pharm· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell mechanics provides a sensitive and quantitative means for probing amyloid-beta peptide and neuronal cell interactions.
Valentin Lulevich, Christopher C Zimmer, Hyun-seok Hong, Lee-way Jin, Gang-yu Liu

Proc Natl Acad Sci U S A· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of tolvaptan on dyspnoea relief from the EVEREST trials.
Peter S Pang, Marvin A Konstam, Holly B Krasa, Karl Swedberg, Faiez Zannad, Christopher Zimmer

Eur Heart J· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
John E A Blair, Sadiya Khan, Marvin A Konstam, Karl Swedberg, Faiez Zannad, Christopher A Zimmer

Eur Heart J· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
John E A Blair, Faiez Zannad, Marvin A Konstam, Thomas Cook, Brian Traver, Christopher Zimmer

J Am Coll Cardiol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
James E Udelson, Cesare Orlandi, John Ouyang, Holly Krasa, Christopher A Zimmer

J Am Coll Cardiol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
Norman C Wang, Aldo P Maggioni, Marvin A Konstam, Faiez Zannad, Holly B Krasa, Christopher Zimmer

JAMA· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of photolithography to encode cell adhesive domains into protein microarrays.
Ji Youn Lee, Sunny S Shah, Christopher C Zimmer, Gang-Yu Liu, Alexander Revzin

Langmuir· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Susan E Shoaf, Steven L Bramer, Patricia Bricmont, Christopher A Zimmer

J Cardiovasc Pharmacol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
James E Udelson, Frank A McGrew, Enrique Flores, Hassan Ibrahim, Stewart Katz, Christopher Zimmer

J Am Coll Cardiol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Marvin A Konstam, Mihai Gheorghiade, John C Burnett, Liliana Grinfeld, Aldo P Maggioni, Christopher Zimmer

JAMA· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, Liliana Grinfeld, Aldo P Maggioni, Christopher Zimmer

JAMA· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan for the treatment of hyponatremia and congestive heart failure.
Cesare Orlandi, Christopher A Zimmer, Mihai Gheorghiade

Future Cardiol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Lisa C Costello-Boerrigter, William B Smith, Guido Boerrigter, John Ouyang, Christopher A Zimmer

Am J Physiol Renal Physiol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure.
Paul J Hauptman, Christopher Zimmer, James Udelson, Susan E Shoaf, Suresh Mallikaarjun

J Cardiovasc Pharmacol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of vasopressin antagonists in the management of acute decompensated heart failure.
Cesare Orlandi, Christopher A Zimmer, Mihai Gheorghiade

Curr Heart Fail Rep· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Mihai Gheorghiade, Cesare Orlandi, John C Burnett, David Demets, Liliana Grinfeld, Christopher Zimmer

J Card Fail· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis